Section Arrow
SNDX.NASDAQ
- Syndax Pharmaceuticals
Quotes are at least 15-min delayed:2025/07/22 19:32 EDT
After Hours
Last
 10.3035
-0.0065 (-0.06%)
Bid
10.05
Ask
10.31
High 10.32 
Low 10.08 
Volume 54144 
Regular Hours
Last
 10.31
+0.58 (+5.96%)
Day High 
10.37 
Prev. Close
9.73 
1-M High
10.02 
Volume 
1.89M 
Bid
10.05
Ask
10.31
Day Low
9.68 
Open
9.79 
1-M Low
8.585 
Market Cap 
837.24M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 9.46 
20-SMA 9.26 
50-SMA 9.93 
52-W High 23.37 
52-W Low 8.58 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.85/-1.63
Enterprise Value
1.17B
Balance Sheet
Book Value Per Share
2.50
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
23.68M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.053+0.002+3.92%-- 
After Hours 0.0528 -0.0002 -0.38%
PLRZPolyrizon Ltd1.45+0.5422+59.73%-- 
After Hours 1.93 +0.48 +33.10%
REPLReplimune Group2.805-9.52-77.24%-- 
After Hours 2.8 -0.005 -0.18%
IOVAIovance Biotherapeutics3.13+0.64+25.70%-- 
After Hours 3.25 +0.12 +3.83%
TNFATNF Pharmaceuticals Inc.0.107-0.0224-17.31%-- 
After Hours 0.1077 +0.0007 +0.65%
Quotes are at least 15-min delayed:2025/07/22 19:32 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.